XORTX Therapeutics, Inc. (XRTX)
1.70
-0.01
(-0.58%)
USD |
NASDAQ |
Sep 29, 16:00
1.58
-0.12
(-7.06%)
After-Hours: 20:00
XORTX Therapeutics Enterprise Value : 1.965M for Sept. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 28, 2026 | 1.965M |
| September 25, 2026 | 1.931M |
| September 24, 2026 | 1.983M |
| September 23, 2026 | 1.948M |
| September 22, 2026 | 2.225M |
| September 21, 2026 | 2.381M |
| September 18, 2026 | 2.329M |
| September 17, 2026 | 1.879M |
| September 16, 2026 | 2.086M |
| September 15, 2026 | 2.260M |
| September 14, 2026 | 2.588M |
| September 11, 2026 | 3.038M |
| September 10, 2026 | 2.658M |
| September 09, 2026 | 2.741M |
| September 08, 2026 | 2.952M |
| September 04, 2026 | 3.004M |
| September 03, 2026 | 2.727M |
| September 02, 2026 | 3.298M |
| September 01, 2026 | 2.744M |
| August 31, 2026 | 3.021M |
| August 28, 2026 | 3.052M |
| August 27, 2026 | 3.229M |
| August 26, 2026 | 2.844M |
| August 25, 2026 | 2.917M |
| August 24, 2026 | 2.467M |
| Date | Value |
|---|---|
| August 21, 2026 | 2.536M |
| August 20, 2026 | 2.502M |
| August 19, 2026 | 2.467M |
| August 18, 2026 | 2.548M |
| August 17, 2026 | 2.571M |
| August 14, 2026 | 2.735M |
| August 13, 2026 | 2.796M |
| August 12, 2026 | 2.746M |
| August 11, 2026 | 2.791M |
| August 10, 2026 | 2.744M |
| August 07, 2026 | 2.692M |
| August 06, 2026 | 2.519M |
| August 05, 2026 | 2.796M |
| August 04, 2026 | 2.744M |
| August 03, 2026 | 2.692M |
| July 31, 2026 | 2.675M |
| July 30, 2026 | 2.502M |
| July 29, 2026 | 2.571M |
| July 28, 2026 | 2.554M |
| July 27, 2026 | 2.502M |
| July 24, 2026 | 2.510M |
| July 23, 2026 | 2.640M |
| July 22, 2026 | 2.484M |
| July 21, 2026 | 2.536M |
| July 20, 2026 | 2.484M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Lexaria Bioscience Corp. | 1.405M |
| InMed Pharmaceuticals, Inc. | 5.028M |
| Target Group, Inc. (Canada) | 11.47M |
| NervGen Pharma Corp. | 138.88M |
| Milestone Pharmaceuticals, Inc. | 70.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.691M |
| Total Expenses (Quarterly) | 1.691M |
| EPS Diluted (Quarterly) | -1.045 |
| Earnings Yield | -161.4% |
| Normalized Earnings Yield | -167.72 |